JMJassi Michell-Sodhi

Jassi Michell-Sodhi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jassi Michell-Sodhi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Anna G. Mayhew

    John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

    2 shared publications
  • Chiara Marini-Bettolo

    John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; and

    2 shared publications
  • Dionne Moat

    John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; and

    2 shared publications
  • Emma Grover

    John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; and

    2 shared publications
  • Emma-Jayne Robinson

    John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; and

    2 shared publications
  • Jordi Díaz-Manera

    The John Walton Muscular Dystrophy Research Center, Newcastle University Translational and Clinical Research Institute, Newcastle Upon Tyne, UK

    2 shared publications

Latest Publications

  • Open Access

    Assessing the Relationship of Quality of Life With Functional Status in a Large Cohort of Adult Patients With Neuromuscular Disorders

    by Karen S.W. Wong, Anando Sen, Jassi Michell-Sodhi, Dionne Moat, Michelle McCallum, Mark Richardson, Elizabeth Harris, Anna G. Mayhew, Michela Guglieri, Emma Grover, et al.

    Health-related quality of life (HR-QoL) is compromised in patients with neuromuscular disorders (NMDs). Disease severity alone does not predict HR-QoL; there are other known predictors including physical, psychological, and social factors. This study aims to provide insight into how mobility, age, and diagnosis may affect HR-QoL in adults with NMD. The QoL in Genetic Neuromuscular Disease Questionnaire (QoL-gNMD) was completed by adult patients with NMDs before attending a clinical visit at the John Walton Muscular Dystrophy Research Centre in Newcastle upon Tyne, UK. The Summary of Function Scale was administered during the clinical visit to characterize mobility status. A total of 580 responses were included in this cross-sectional study. Overall perceived health and HR-QoL were reported poorest by ambulant patients who walked using aids. Items from the QoL-gNMD that were affected the most by NMDs were future planning and the need to rely more on others. A nonlinear trend where patients with “midlevel” mobility (walked with aids or manual wheelchair users) reported the poorest HR-QoL were observed in all 3 HR-QoL domains: Impact of Physical Symptoms (IPSs), Self-Perception (SP), and Activities and Social Participation (ASP). This nonlinear trend between HR-QoL and mobility was observed for younger patients but became more linear in older age groups. In our cohort, patients with “midlevel” mobility were the oldest, and those with the lowest levels of mobility (i.e., powered wheelchair users) were the youngest. Interaction between age and mobility was significant and both affected HR-QoL. There was marked variability in HR-QoL between diagnoses. Diagnosis was a significant factor for IPS (p < 0.01) and SP (p = 0.04) but not for ASP (p = 0.17). Age and mobility status affect HR-QoL. Individuals with limited ambulation reported the poorest HR-QoL, which was partially restored in powered wheelchair users, to levels comparable with more ambulant patients. However, the positive effect of wheelchair use became less substantial as patients get older. There was also marked variability in HR-QoL between diagnoses that was unrelated to physical disability. These findings provide evidence to guide care management discussions and highlight the importance of timely introduction of powered mobility.


  • Open Access

    Motor Function in Limb-Girdle Muscular Dystrophy R1/2A

    by Meredith K. James, Megan A. Iammarino, Natalie F. Reash, Christopher L. Steiner, Audrey B. Knight, Melissa A. Smith, Dionne Moat, Jassi Michell-Sodhi, Karen S.W. Wong, Emma Grover, et al.

    Limb-girdle muscular dystrophy (LGMD) type R1/2A, calpain-3-related, is a rare, autosomal recessive disorder caused by pathogenic variants in the CAPN3 gene. LGMDR1/2A causes progressive weakness of upper and lower limbs, leading to difficulty walking and use of arms for overhead activities. The rate of progression of LGMDR1/2A is unknown because of the limited number of published cohorts and the lack of validated outcome measures. Quantifying the natural history of LGMDR1/2A using standardized outcome measures is critical for understanding the rate of disease progression and improving clinical care and clinical trial readiness. The aim of this cross-sectional study was to evaluate the suitability of the North Star Assessment for limb-girdle type muscular dystrophies (NSAD), 100-meter timed test (100MTT), and Performance of Upper Limb 2.0 (PUL) as outcome measures for quantifying disease presentation and progression in individuals with LGMDR1/2A. Ninety-two individuals were evaluated by physiotherapy teams at Nationwide Children's Hospital and the John Walton Muscular Dystrophy Research Centre. Psychometric analysis of NSAD and PUL was completed using Rasch measurement methods. Descriptive statistics and correlation coefficients explored the relationship among all outcomes. Psychometric analyses demonstrated that NSAD and PUL were valid and appropriate functional outcome measures for ambulant and nonambulant individuals with LGMDR1/2A. The NSAD and 100MTT velocity were highly correlated (Spearman rho Rs(88) = 0.89) The 100MTT was particularly useful for the strongest and asymptomatic cohort. In this largest reported cohort of individuals with LGMDR1/2A, NSAD, PUL, and 100MTT were suitable to quantify functional impact of the disease. International harmonization of outcome measures creates meaningful clinical data to inform clinical management and trial design.